Proteome Sciences plc Share Price

Equities

PRM

GB0003104196

Medical Equipment, Supplies & Distribution

Market Closed - London S.E. 09:05:28 26/04/2024 pm IST 5-day change 1st Jan Change
4.15 GBX +18.23% Intraday chart for Proteome Sciences plc +25.76% -8.39%

Financials

Sales 2022 7.78M 9.74M 812M Sales 2023 5.03M 6.3M 525M Capitalization 13.37M 16.75M 1.4B
Net income 2022 1M 1.25M 104M Net income 2023 -2M -2.5M -209M EV / Sales 2022 2.35 x
Net Debt 2022 7.92M 9.92M 827M Net Debt 2023 11.45M 14.34M 1.2B EV / Sales 2023 4.94 x
P/E ratio 2022
8.14 x
P/E ratio 2023
-5.46 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 78.76%
More Fundamentals * Assessed data
Dynamic Chart
1 day+18.23%
1 week+25.76%
Current month+22.42%
1 month+22.42%
3 months-9.59%
6 months-34.39%
Current year-8.39%
More quotes
1 week
3.02
Extreme 3.02
4.64
1 month
2.65
Extreme 2.6504
4.64
Current year
2.65
Extreme 2.6504
5.75
1 year
2.65
Extreme 2.6504
8.79
3 years
2.65
Extreme 2.6504
10.00
5 years
2.25
Extreme 2.25
10.00
10 years
2.20
Extreme 2.2005
43.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 15/20/15
Director of Finance/CFO 48 01/22/01
Chairman 71 10/93/10
Members of the board TitleAgeSince
Chairman 71 10/93/10
Director/Board Member 69 01/14/01
Director/Board Member 72 01/17/01
More insiders
Date Price Change Volume
26/24/26 4.15 +18.23% 423,867
25/24/25 3.51 +0.29% 412
24/24/24 3.5 +7.69% 0
23/24/23 3.25 0.00% 0
22/24/22 3.25 -1.52% 500

Delayed Quote London S.E., April 26, 2024 at 09:05 pm IST

More quotes
Proteome Sciences plc is a specialist provider of contract proteomics services. The services enable drug discovery, development, and biomarker identification and employ workflows for the optimum analysis of tissues, cells, and body fluids. Its principal activities involve protein biomarker research and development. It uses high-sensitivity techniques to detect and characterize differentially expressed proteins in biological samples for diagnostic, prognostic, and therapeutic applications. SysQuant and TMT MS2 are its unbiased methods for identifying and contextualizing new targets and defining mechanisms of biological activity, while analysis using super-depletion and TMTcalibrator provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. In addition, it has invented and developed the technology for TMT and TMTpro, and manufactures these small, protein-reactive chemical reagents, which are sold for multiplex quantitative proteomics.
More about the company